This phase 3 randomized controlled trial enrolled 6000 children aged 10 to 14 years with at least 2 active caries lesions across 3 centers in China. Participants were randomized to receive either 8.0% arginine dentifrice, 1.5% arginine dentifrice, or 0.32% sodium fluoride (NaF) dentifrice as control.
After 2 years, the 8% arginine dentifrice group showed a statistically significant reduction of 26.0% in DMFS scores compared to control (effect size -0.16; 95% CI, -0.22 to -0.10; P < .001) and a 25.3% reduction in DMFT scores (effect size -0.17; 95% CI, -0.24 to -0.11; P < .001). In contrast, the 1.5% arginine dentifrice showed no statistical difference versus control for DMFS (effect size -0.01; 95% CI, -0.07 to 0.05; P = .819) or DMFT (effect size -0.01; 95% CI, -0.07 to 0.05; P = .739).
Safety and tolerability data were not reported in this study. Limitations were not explicitly listed, but the lack of absolute numbers and adverse event reporting limits the interpretation of clinical significance.
For practice, arginine dentifrices may serve as effective alternatives to fluoride for anticaries protection in children, though only the 8% concentration demonstrated superiority in this trial.
View Original Abstract ↓
BACKGROUND: Dental caries remains a significant oral health burden globally. Scientific evidence has demonstrated the dose-dependent anticaries action of fluoride; however, more effective, comprehensive, and alternative prevention strategies are required.
METHODS: A 2-y, phase 3, randomized controlled trial based on a double-blind, 3-arm, parallel-group design was conducted from April 15, 2019, through March 12, 2022 across 3 centers in China. Six thousand children aged 10 to 14 y with ≥2 active caries lesions were assigned 1 of 3 study dentifrices: 8.0% arginine, 1.5% arginine, and 0.32% sodium fluoride (NaF). The primary efficacy outcomes were incremental DMFS (decayed, missing, and filled surfaces) and DMFT (decayed, missing, and filled teeth) caries indices scores after 2 y of product use. The secondary efficacy outcomes were the incremental caries indices scores after 1 y and 6 mo of product use. Noninferiority was achieved if the 95% CI of the mean difference in scores was below the noninferiority margin of 0.2545 after 2 y, 1 y, and 6 mo of product use.
RESULTS: After 2 y, the 8.0% arginine-containing dentifrice demonstrated a statistically significant reduction of 26.0% in DMFS scores (-0.16; 95% CI, -0.22 to -0.10; P < .001) and 25.3% in DMFT scores (-0.17; 95% CI, -0.24 to -0.11; P < .001) versus control. No statistical difference was measured between the 1.5% arginine-containing dentifrice and control in DMFS (-0.01; 95% CI, -0.07 to 0.05; P = .819) and DMFT (-0.01; 95% CI, -0.07 to 0.05; P = .739).
CONCLUSIONS: Dentifrice containing 8.0% arginine showed a statistically significant reduction in caries incidence versus the NaF control, while the 1.5% arginine dentifrice showed equivalence to the NaF control regarding caries reduction. This clinical study confirms that arginine dentifrices are effective alternatives to fluoride in providing anticaries protection.Knowledge Transfer Statement:This study demonstrates that arginine is an efficacious anticaries agent at the examined doses of 1.5% and 8%. Clinicians and consumers can consider this a new caries preventive agent providing choice to people seeking fluoride-free alternatives. Policy makers could leverage these findings to guide oral health initiatives and inform regulations on dentifrice composition, promoting broader access to effective caries prevention methods.